[{"id":"68b53629-bd68-4ac5-8c30-b43bdf31b541","acronym":"","url":"https://clinicaltrials.gov/study/NCT05552807","created_at":"2022-09-23T17:07:08.783Z","updated_at":"2024-07-02T16:36:03.566Z","phase":"Phase 1","brief_title":"SCT200 in Combination With SCT-I10A/Paclitaxel/Docetaxel in Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma","source_id_and_acronym":"NCT05552807","lead_sponsor":"Sinocelltech Ltd.","biomarkers":" PD-L1","pipe":" | ","alterations":" PD-L1 expression","tags":["PD-L1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PD-L1 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e paclitaxel • docetaxel • SCT200 • Anyouping (finotonlimab)"],"overall_status":"Recruiting","enrollment":" Enrollment 120","initiation":"Initiation: 06/15/2022","start_date":" 06/15/2022","primary_txt":" Primary completion: 09/01/2023","primary_completion_date":" 09/01/2023","study_txt":" Completion: 09/01/2023","study_completion_date":" 09/01/2023","last_update_posted":"2022-09-23"},{"id":"72519d3f-752b-4277-8040-a73d5b7a0d41","acronym":"","url":"https://clinicaltrials.gov/study/NCT04146402","created_at":"2021-01-18T20:14:15.185Z","updated_at":"2024-07-02T16:36:50.436Z","phase":"Phase 3","brief_title":"SCT-I10A Plus Standard Chemotherapy in First-line Recurrent/ Metastatic Head and Neck Squamous Cell Carcinoma","source_id_and_acronym":"NCT04146402","lead_sponsor":"Sinocelltech Ltd.","biomarkers":" PD-L1","pipe":"","alterations":" ","tags":["PD-L1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cisplatin • Anyouping (finotonlimab)"],"overall_status":"Unknown status","enrollment":" Enrollment 330","initiation":"Initiation: 12/31/2019","start_date":" 12/31/2019","primary_txt":" Primary completion: 01/29/2022","primary_completion_date":" 01/29/2022","study_txt":" Completion: 07/30/2022","study_completion_date":" 07/30/2022","last_update_posted":"2020-02-05"},{"id":"7d57b274-e5e9-415c-9897-3342bdcf5c90","acronym":"","url":"https://clinicaltrials.gov/study/NCT04146181","created_at":"2021-01-18T20:18:56.346Z","updated_at":"2024-07-02T16:36:52.569Z","phase":"Phase 2","brief_title":"Safety and Efficacy of SCT-I10A in Head and Neck Squamous Cell Carcinoma","source_id_and_acronym":"NCT04146181","lead_sponsor":"Sinocelltech Ltd.","biomarkers":" PD-L1","pipe":"","alterations":" ","tags":["PD-L1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cisplatin • Anyouping (finotonlimab)"],"overall_status":"Unknown status","enrollment":" Enrollment 103","initiation":"Initiation: 10/31/2019","start_date":" 10/31/2019","primary_txt":" Primary completion: 06/30/2021","primary_completion_date":" 06/30/2021","study_txt":" Completion: 09/30/2021","study_completion_date":" 09/30/2021","last_update_posted":"2019-12-12"}]